TMO · a US exchange · USD · Market cap $223.0B · 125,000 employees
Thermo Fisher Scientific Inc.
FAIL · Does not pass the screen
603.02 USD
At the last full screen 2026-09-08
Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Thermo Fisher Scientific holds its Accumulation at $603.02. The statistical read favours the sellers, held for 22 days.
As held on the ledger · 2026-09-08
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 22 days
Price at the screen
$603.02
Valuation
32.42 trailing · 21.91 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.69%
Below 33%
Interest-bearing debt is 35.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.23%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
16.99%
Below 49%
Money owed to the company is 17.0% of assets, under the 49% limit.
Pass
Revenue purity
2.23%
Below 5%
Only 2.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience Overlay
Conscience flag · AFSC Investigate
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 4% discount to our $627.81 fair value, moderate competitive moat, 10.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 4.1% margin of safety to the base estimate.
Third-party analyst targets: 27 covering, consensus Buy. The average target sits +8% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
High-flying Healthcare Stock, But Debt Raises Eyebrows
Imagine a global lab tech powerhouse, Thermo Fisher Scientific, equipping researchers, doctors, and scientists alike with cutting-edge tools to uncover the mysteries of life. It's a company at the forefront of healthcare diagnostics, with a revenue growth of a robust 10%. Why we pass, however, is a glaring debt ratio issue that fails our ethical screen, casting a shadow over its otherwise impressive credentials.
Despite a forward P/E of 22.8x, suggesting a premium valuation, and a matching market consensus target of $642, the underlying debt concerns are substantial enough to warrant caution. Its 15% profit margin and 14% ROE signal a healthy business, yet the ethical lapse poses a risk to long-term stability and sustainability, a critical factor in our investment thesis.
Risk sits in the form of this debt-induced ethical failing, which, while not immediately impacting the bottom line, could hold back the stock from reaching its full potential. As responsible investors, we must consider not just financial metrics but also the broader implications of corporate responsibility. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TMO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-23Markup · changed$627.55+17.9%Entry 10
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612.
2026-07-22Distribution$532.48+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Distribution$532.48+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Distribution$532.48+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Distribution$532.48+12.6%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$472.80+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Distribution$472.80+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Distribution$472.80+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it strong buy, with a mean price target of $612. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Distribution$472.80+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$472.80Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.